Medicare GLP-1 Bridge Cost 2026: How $50/Month Works, Part D Implications & 2028 Cliff

Last updated: May 11, 2026 · Reading time: 10 minutes

The headline price for the Medicare GLP-1 Bridge is $50 per month. That’s the number every news article leads with, and it’s accurate: eligible beneficiaries pay $50 for a monthly supply of Wegovy, Zepbound KwikPen, or Foundayo starting July 1, 2026. But $50 isn’t the whole cost story. The Bridge operates outside the normal Part D benefit structure, which means the $50 doesn’t behave like a regular copay. It doesn’t count toward your deductible. It doesn’t count toward your $2,100 annual out-of-pocket cap. And Extra Help recipients can’t apply their subsidy to it.

This guide breaks down exactly what you’ll pay, what the $50 does and doesn’t cover, how it compares to other ways of paying for GLP-1s, and the financial traps to watch out for. For the program rules in general, see our complete guide to the Medicare GLP-1 Bridge.

Bridge Cost: The 60-Second Summary

What you pay: $50 per month, flat. Same whether you’re on the starting dose or the maximum dose, same whether you’re filling Wegovy, Zepbound KwikPen, or Foundayo.

What “one month” means: 28 days of medication. One Zepbound KwikPen contains four weekly doses. One box of Wegovy injection pens contains four. One bottle of Wegovy pills covers a month. Foundayo is a monthly supply of daily pills.

The first catch: Bridge payments don’t count toward your Part D deductible, your $2,100 annual out-of-pocket cap (2026), or your $2,400 cap (2027). You can spend $600 on Bridge drugs in a year and still owe your full Part D deductible on everything else.

The second catch: Beneficiaries with Extra Help (Low-Income Subsidy) can’t apply their subsidy to Bridge drugs. The $50 is the $50, even if you normally pay $1.55 or $4.50 for most prescriptions.

What it replaces: Cash prices of $149-$699 per month for GLP-1 weight-loss drugs without coverage. A 70-90% savings if you qualify.

How the $50 Actually Works

The Bridge price is a fixed copay, not a percentage of the drug cost. Here’s the money flow under the hood, according to CMS guidance:

Manufacturers (Novo Nordisk and Eli Lilly) agreed to provide eligible drugs at a net price of $245 per monthly supply.
The beneficiary pays $50 at the pharmacy counter.
A central processor (Humana, operating under its Limited Income Newly Eligible Transition infrastructure) reimburses the pharmacy at the drug’s wholesale acquisition cost minus the $50 copay, plus a dispensing fee.
The manufacturer pays CMS the difference between the wholesale acquisition cost and the agreed $245 net price.

You don’t need to understand any of that to use the program. From your perspective, you walk in, the pharmacist processes the claim, you pay $50, you leave. The behind-the-scenes math is what makes the $50 price possible without requiring legislation to change Medicare’s existing rules about weight-loss drug coverage.

What “$50” specifically means by drug:

Wegovy injection: $50 for one box of four single-use pens (one month at the prescribed weekly dose)
Wegovy oral pill: $50 for one bottle of 30 tablets at the prescribed daily dose
Zepbound KwikPen: $50 for one KwikPen, which contains four weekly doses
Foundayo: $50 for one month’s supply of daily pills at the prescribed dose

If your prescriber escalates your dose mid-cycle (going from 0.25 mg to 0.5 mg Wegovy, for instance), the next fill is still $50 at the new dose. Dose changes don’t affect price.

What the $50 Does NOT Count Toward

This is the part most coverage of the Bridge skips, and it’s the most likely thing to cost you more money than you expected if you don’t understand it.

The Bridge operates outside Part D entirely. That means everything you pay under the Bridge happens in a separate accounting bucket from your regular Part D drug costs. According to KFF’s analysis, none of your Bridge spending counts toward your Part D protections.

Your annual Part D deductible. Most Part D plans have a deductible (often around $545 in 2026) that you pay before your drug benefits kick in for non-Bridge medications. Money spent on Bridge drugs doesn’t count toward meeting that deductible. If you take Wegovy and three other Part D drugs, you’re still paying full price for the other three until you’ve separately met your deductible.

Your annual out-of-pocket cap. Medicare Part D caps out-of-pocket spending at $2,100 in 2026 and $2,400 in 2027. Once you hit the cap, you pay $0 for the rest of the calendar year. Bridge spending doesn’t count toward that cap. Six months of Bridge fills equals $300 paid, but your Part D OOP counter still shows $0.

Your “true out-of-pocket” (TrOOP) tally. Medicare tracks something called TrOOP for purposes of the standard Part D benefit phases. Bridge spending doesn’t add to TrOOP either.

For most beneficiaries, these distinctions don’t matter much. If you only take Bridge drugs and a handful of cheap generics, you’re paying $50 and not much else either way. But if you’re a high-cost-sharing beneficiary on multiple expensive medications, the lack of Bridge integration can mean meaningfully higher total drug spending than you’d intuitively expect.

A worked example: a beneficiary on Wegovy ($50/month under Bridge) and three other Part D medications costing $200/month combined would expect to hit the $2,100 OOP cap by month 8. Under the Bridge structure, only the $200/month counts toward the cap. They hit the cap by month 11 instead, paying an extra $1,800 across the year compared to a scenario where Bridge spending counted.

[LEAD FORM PLACEHOLDER: “See if you qualify for $50 GLP-1 coverage”]

The Extra Help (LIS) Exclusion

The Low-Income Subsidy, commonly called Extra Help, is a Medicare program that helps lower-income beneficiaries pay for prescription drugs. Under Extra Help, most prescriptions cost $1.55 to $4.50, depending on your specific eligibility level. About 14 million Medicare beneficiaries qualify for some level of Extra Help.

Extra Help does not apply to Bridge drugs.

According to CMS guidance, the Bridge operates independently of Extra Help. Beneficiaries with Extra Help still pay the full $50 for Bridge drugs. This is the policy choice that drew the most criticism from advocates when the program was announced.

As KFF’s Juliette Cubanski put it to KFF Health News, $50 a month “is a lot of money for somebody who’s living on a $750-a-month Social Security check.” Extra Help recipients are, by definition, low-income beneficiaries. The Bridge’s $50 price is more accessible than the cash price, but it’s not equivalent to the deeply subsidized pricing Extra Help recipients pay for other drugs.

For Medicare beneficiaries with Extra Help who can’t afford $50 a month for Bridge drugs:

Manufacturer patient assistance programs still exist and may provide additional discounts. Novo Nordisk and Eli Lilly both run programs, though eligibility rules vary.
Some state Medicaid programs cover GLP-1s for weight loss for dually-eligible beneficiaries; this is independent of the Bridge.
Compounded GLP-1s are not covered under Medicare in any form, but cash prices through telehealth platforms can be lower than $50, with significant safety and consistency caveats.

This is a real gap in the program that hasn’t been closed. If you have Extra Help and need help affording Bridge drugs, ask your prescriber about manufacturer assistance programs or whether your state Medicaid covers any GLP-1s for weight loss.

Bridge Cost vs. Standard Part D Cost for the Same Drug

Here’s where it gets confusing. The same GLP-1 drug can cost different amounts under Medicare depending on what’s written on the prior authorization.

Wegovy at $50 (Bridge): Written for obesity. Eligibility per Bridge criteria. Covered through central processor.

Wegovy at variable Part D price: Written for cardiovascular risk reduction. Covered through your Part D plan at whatever copay your formulary applies. Some plans charge $25-50 (cheaper than Bridge); some charge $200-400 (more expensive than Bridge).

Zepbound at $50 (Bridge): Written for obesity. KwikPen only. Eligibility per Bridge criteria.

Zepbound at variable Part D price: Written for obstructive sleep apnea. Covered through your Part D plan at whatever copay your formulary applies.

The complication: if you have both a qualifying condition for the Bridge (obesity with one of the eligibility pathways) and a qualifying condition for Part D coverage (cardiovascular disease for Wegovy, OSA for Zepbound), you can technically be prescribed either way. The prior authorization indication determines which pathway you go through.

Three scenarios to think about:

Your Part D plan has the drug on a low tier with a $20-40 copay. Part D wins. You pay less and it counts toward your protections.
Your Part D plan has the drug on a high tier with a $150-400 copay. Bridge wins. You pay less.
You’re a high drug spender approaching your OOP cap. Part D may be more valuable because the spending counts toward your cap, after which you pay $0 for the rest of the year.

There’s no universal answer. Check your plan’s formulary, see what tier the drug is on, calculate your expected annual spending, and talk to your prescriber about which indication makes financial sense. For some beneficiaries, the choice could affect annual drug spending by hundreds of dollars.

Bridge Cost vs. Manufacturer Self-Pay Programs

Both Novo Nordisk and Eli Lilly run direct-to-consumer self-pay programs for their GLP-1 drugs, separate from insurance. These existed before the Bridge and continue to operate.

Wegovy self-pay (via NovoCare Pharmacy): $499 per month for all doses through direct purchase. Lower for lower doses through specific subscription offerings.

Zepbound self-pay (via LillyDirect): $299 for the 2.5 mg starting dose, $399-449 for higher doses. Available in either KwikPen or vials.

Foundayo self-pay (via LillyDirect): Starts at $149 for the lowest dose. Higher doses are $349.

For Medicare beneficiaries, the Bridge ($50) is dramatically cheaper than any manufacturer self-pay program. The only reason to use a self-pay program if you’re Medicare-eligible would be if you don’t qualify for the Bridge (you don’t meet the BMI thresholds, or you don’t have a qualifying condition) but still want the medication.

If you’re not eligible for the Bridge but are eligible for Medicare and have cardiovascular disease, the Wegovy CV indication through Part D is usually a better deal than self-pay. If you’re not eligible for the Bridge and don’t have a qualifying Part D indication, self-pay programs become the practical option, and you’d compare them on dose, format, and out-of-pocket cost.

Cash Price Comparison

For context on what the $50 Bridge price replaces, here’s what GLP-1 weight-loss drugs cost without insurance or manufacturer programs, based on retail pharmacy listings as of May 2026:

Wegovy injection (4-pen box): $1,349 retail. After manufacturer coupons and discount cards: $499-799.
Wegovy oral pill: $1,349 retail. After coupons: similar to injection.
Zepbound KwikPen: $1,086 retail. After coupons: $299-449 via LillyDirect.
Foundayo: $539-$1,047 retail depending on dose. After coupons: $149-349 via LillyDirect.

The Bridge at $50 represents an 80-95% reduction from typical out-of-pocket costs for these drugs. For a Medicare beneficiary on a fixed income, that’s the difference between “I can afford this” and “I can’t.”

For a fuller breakdown of cash prices and manufacturer programs, see Manufacturer GLP-1 savings programs explained (coming soon).

Frequently Asked Questions

Does the $50 ever change during the demonstration?

No. CMS has committed to $50 as the fixed beneficiary copay for the duration of the Bridge (July 1, 2026 through December 31, 2027). Dose increases, drug switches, and dispensing fees don’t change what you pay at the counter.

What about taxes or pharmacy fees?

The $50 includes any dispensing fee. You shouldn’t be charged extra at the counter. If your pharmacy adds fees on top of the $50, that’s a billing error; ask them to correct it.

Can I use a discount card or coupon on top of the $50?

No. The Bridge is structured around a fixed beneficiary cost. Manufacturer savings cards and pharmacy discount cards generally don’t stack with Medicare benefits, and the Bridge specifically excludes coupon stacking.

What if I have supplemental insurance?

Most Medicare supplemental plans (Medigap) don’t cover Part D drugs. Some employer-sponsored or retiree health plans provide additional drug coverage that may offset the $50. Check with your specific supplemental plan.

Do I have to pay $50 up front, or can it be billed?

The $50 is paid at the pharmacy counter at the time of dispensing, like any other prescription copay. Most pharmacies accept the usual payment methods (credit card, cash, FSA/HSA cards).

What happens if my pharmacy charges me more than $50?

That’s a billing error. Ask the pharmacist to re-run the claim with the correct BIN (028918) and PCN (MEDDGLP1BR). If the issue persists, contact your Part D plan or the CMS Bridge central processor.

Will the $50 price continue after December 2027?

Unknown. The Bridge expires December 31, 2027, with a planned transition to the BALANCE Model in 2028. Whether the $50 price survives depends on negotiations with Part D plans and manufacturers that haven’t happened yet. See our coverage of what happens after the Bridge ends for more.

Sources and References

This guide is for informational purposes only and is not financial or medical advice. Specific cost outcomes depend on your Part D plan, your eligibility under the Bridge, and your overall drug spending. Weight Loss RX Guide is not affiliated with CMS, Medicare, Eli Lilly, or Novo Nordisk. We may receive compensation when readers connect with services through links on this site; see our affiliate disclosure for details.